BioCentury
ARTICLE | Clinical News

LX1032: Phase II started

July 13, 2009 7:00 AM UTC

Lexicon began a double-blind, placebo-controlled, dose-escalation, U.S. Phase II trial to evaluate up to 4 dose levels of oral LX1032 in about 28 patients for 4 weeks. LX1032 has Fast Track designatio...